TGFB1 and neoplasm: Reduced TGF-β signaling in stromal cells, antitumor immunity and regression, and facilitated T-cell penetration into the center of the tumor have been found in preclinical studies investigating the combination of a TGF-β inhibitor and anti-PD-L1 agent.23-25